Literature DB >> 29662829

Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma.

Masatoshi Kudo1.   

Abstract

Entities:  

Year:  2018        PMID： 29662829      PMCID： PMC5892376          DOI： 10.1159/000487148

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  46 in total

1.  Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials.

Authors:  Richard Jackson; Eftychia-Eirini Psarelli; Sarah Berhane; Harun Khan; Philip Johnson
Journal:  J Clin Oncol       Date:  2017-01-03       Impact factor: 44.544

2.  Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2016-12-15       Impact factor: 11.740

3.  Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.

Authors:  Eric T Sawey; Maia Chanrion; Chunlin Cai; Guanming Wu; Jianping Zhang; Lars Zender; Alice Zhao; Ronald W Busuttil; Herman Yee; Lincoln Stein; Dorothy M French; Richard S Finn; Scott W Lowe; Scott Powers
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

4.  Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade.

Authors:  Nicolò Rigamonti; Ece Kadioglu; Ioanna Keklikoglou; Céline Wyser Rmili; Ching Ching Leow; Michele De Palma
Journal:  Cell Rep       Date:  2014-07-31       Impact factor: 9.423

Review 5.  Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy.

Authors:  Damien Gerald; Sudhakar Chintharlapalli; Hellmut G Augustin; Laura E Benjamin
Journal:  Cancer Res       Date:  2013-03-06       Impact factor: 12.701

6.  Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.

Authors:  Valérie Vilgrain; Helena Pereira; Eric Assenat; Boris Guiu; Alina Diana Ilonca; Georges-Philippe Pageaux; Annie Sibert; Mohamed Bouattour; Rachida Lebtahi; Wassim Allaham; Hélène Barraud; Valérie Laurent; Elodie Mathias; Jean-Pierre Bronowicki; Jean-Pierre Tasu; Rémy Perdrisot; Christine Silvain; René Gerolami; Olivier Mundler; Jean-Francois Seitz; Vincent Vidal; Christophe Aubé; Frédéric Oberti; Olivier Couturier; Isabelle Brenot-Rossi; Jean-Luc Raoul; Anthony Sarran; Charlotte Costentin; Emmanuel Itti; Alain Luciani; René Adam; Maïté Lewin; Didier Samuel; Maxime Ronot; Aurelia Dinut; Laurent Castera; Gilles Chatellier
Journal:  Lancet Oncol       Date:  2017-10-26       Impact factor: 41.316

7.  SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

Authors:  Andrew X Zhu; Olivier Rosmorduc; T R Jeffry Evans; Paul J Ross; Armando Santoro; Flair Jose Carrilho; Jordi Bruix; Shukui Qin; Paul J Thuluvath; Josep M Llovet; Marie-Aude Leberre; Markus Jensen; Gerold Meinhardt; Yoon-Koo Kang
Journal:  J Clin Oncol       Date:  2014-12-29       Impact factor: 44.544

8.  Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.

Authors:  Osamu Tohyama; Junji Matsui; Kotaro Kodama; Naoko Hata-Sugi; Takayuki Kimura; Kiyoshi Okamoto; Yukinori Minoshima; Masao Iwata; Yasuhiro Funahashi
Journal:  J Thyroid Res       Date:  2014-09-10

9.  Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.

Authors:  Yuji Yamamoto; Junji Matsui; Tomohiro Matsushima; Hiroshi Obaishi; Kazuki Miyazaki; Katsuji Nakamura; Osamu Tohyama; Taro Semba; Atsumi Yamaguchi; Sachi Suzuki Hoshi; Fusayo Mimura; Toru Haneda; Yoshio Fukuda; Jun-Ichi Kamata; Keiko Takahashi; Masayuki Matsukura; Toshiaki Wakabayashi; Makoto Asada; Ken-Ichi Nomoto; Tatsuo Watanabe; Zoltan Dezso; Kentaro Yoshimatsu; Yasuhiro Funahashi; Akihiko Tsuruoka
Journal:  Vasc Cell       Date:  2014-09-06

10.  Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses.

Authors:  Toshiyuki Tamai; Seiichi Hayato; Seiichiro Hojo; Takuya Suzuki; Takuji Okusaka; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Clin Pharmacol       Date:  2017-05-31       Impact factor: 3.126
View more
  41 in total

Review 1.  Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-11-17       Impact factor: 11.740

2.  Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.

Authors:  MinKe He; QiJiong Li; RuHai Zou; JingXian Shen; WanQiang Fang; GuoSheng Tan; YuanMin Zhou; XiaoPing Wu; Li Xu; Wei Wei; Yong Le; ZhongGuo Zhou; Ming Zhao; Ying Guo; RongPing Guo; MinShan Chen; Ming Shi
Journal:  JAMA Oncol       Date:  2019-07-01       Impact factor: 31.777

3.  Lenvatinib promotes antitumor immunity by enhancing the tumor infiltration and activation of NK cells.

Authors:  Qing Zhang; Hongyan Liu; Hanhan Wang; Mengmeng Lu; Yangna Miao; Jiage Ding; Huizhong Li; Xiaoge Gao; Shishuo Sun; Junnian Zheng
Journal:  Am J Cancer Res       Date:  2019-07-01       Impact factor: 6.166

Review 4.  Implications of Immunotherapy in Hepatobiliary Tumors.

Authors:  Aline Gottlieb; Jan Best; Ali Canbay
Journal:  Visc Med       Date:  2019-02-08

Review 5.  Strategies for the delay of surgery in the management of resectable hepatobiliary malignancies during the COVID-19 pandemic.

Authors:  S Bennett; K Søreide; S Gholami; P Pessaux; C Teh; E Segelov; H Kennecke; H Prenen; S Myrehaug; D Callegaro; J Hallet
Journal:  Curr Oncol       Date:  2020-10-01       Impact factor: 3.677

6.  Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma.

Authors:  Haijing Deng; Anna Kan; Ning Lyu; Luwen Mu; Yi Han; Longzhong Liu; Yanyu Zhang; Youfa Duan; Shuangye Liao; Shaolong Li; Qiankun Xie; Tianxiao Gao; Yanrong Li; Zhenfeng Zhang; Ming Zhao
Journal:  Liver Cancer       Date:  2020-02-25       Impact factor: 11.740

7.  Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib.

Authors:  Haruki Uojima; Makoto Chuma; Yoshiaki Tanaka; Hisashi Hidaka; Takahide Nakazawa; Shogo Iwabuchi; Satoshi Kobayashi; Nobuhiro Hattori; Katsuaki Ogushi; Manabu Morimoto; Tatehiro Kagawa; Katsuaki Tanaka; Makoto Kako; Wasaburo Koizumi
Journal:  Liver Cancer       Date:  2019-12-06       Impact factor: 11.740

Review 8.  Cellular based treatment modalities for unresectable hepatocellular carcinoma.

Authors:  Konstantinos Damiris; Hamza Abbad; Nikolaos Pyrsopoulos
Journal:  World J Clin Oncol       Date:  2021-05-24

9.  Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway.

Authors:  Jianwen Hao; Qizhen Peng; Keruo Wang; Ge Yu; Yi Pan; Xiaoling Du; Na Hu; Xuening Zhang; Yu Qin; Huikai Li
Journal:  Biomed Res Int       Date:  2021-07-22       Impact factor: 3.411

10.  Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib.

Authors:  Yasutoshi Fujii; Atsushi Ono; C Nelson Hayes; Hiroshi Aikata; Masami Yamauchi; Shinsuke Uchikawa; Kenichiro Kodama; Yuji Teraoka; Hatsue Fujino; Takashi Nakahara; Eisuke Murakami; Daiki Miki; Wataru Okamoto; Tomokazu Kawaoka; Masataka Tsuge; Michio Imamura; Kazuaki Chayama
Journal:  J Exp Clin Cancer Res       Date:  2021-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.